Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

<p>The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibitor (ICI)-treated patients enabled in silico prediction and subsequent preclinical validation of multi-gene payload combinations to overcome lack of response to ICI […]</p>
<p>The post <a href="https://forextv.com/top-news/candel-therapeutics-presents-preclinical-data-from-its-enlighten-discovery-platform-at-sitc/">Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>